Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An In Situ-Generated Near-Infrared Chemiluminescent Nanoprobe for High-Contrast Lymph Node Mapping and Tumor-Guided Surgery.

Analytical chemistry·2026
Same author

Engineering Coumarin-Based Afterglow Luminescence Probes for Activatable Imaging Peroxynitrite In Vivo.

Angewandte Chemie (International ed. in English)·2026
Same author

In Vivo-Assembled Artificial Base-Albumin Platform for Tumor-Targeted General Drug Delivery.

ACS nano·2026
Same author

Overcoming Epithelial-Mesenchymal Transition Challenges in Cancer Detection through a Dual-Targeting Strategy.

Nano letters·2025
Same author

Bisboronic Ester-Enabled Redox-Targeted Cancer Therapy: A Cascade ROS Consumption Approach for Efficient Elimination of Cancer Cells.

Journal of medicinal chemistry·2025
Same author

A Bicyclic Dioxetane Chemiluminescence Nanoprobe for Peroxynitrite Imaging in Vivo.

Analytical chemistry·2024

Related Experiment Video

Updated: Sep 9, 2025

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

2.9K

Recent Development of Boron-Containing Small-Molecule Anticancer Agents.

Yi-Miao Guo1, Yue Cui2, Le Yang1,2

  • 1Hunan Provincial Key Laboratory of Cytochemistry, School of Chemistry and Pharmaceutical Engineering, Changsha University of Science and Technology, Changsha 410114, China.

ACS Pharmacology & Translational Science
|August 29, 2025
PubMed
Summary

Boron-based small molecules show promise as anticancer agents. This review covers their structures, mechanisms, and applications, while also addressing challenges and future research directions for these novel therapies.

Keywords:
BNCTanticancerboroninhibitorsmall molecule

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.8K

Related Experiment Videos

Last Updated: Sep 9, 2025

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

2.9K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.8K

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Materials Science

Background:

  • Boron-containing small molecules are gaining attention for their unique properties and potential in cancer treatment.
  • Recent research focuses on developing diverse boron-based agents for therapeutic applications.

Purpose of the Study:

  • To systematically review recent advancements in boron-based small-molecule anticancer agents.
  • To highlight molecular structures, mechanisms of action, and therapeutic applications of these agents.
  • To discuss challenges and future directions in the field of boron-based cancer therapy.

Main Methods:

  • Literature review of recent studies on boron-based small-molecule anticancer agents.
  • Categorization of agents based on therapeutic approach (e.g., BNCT, enzyme inhibition, ROS targeting).
  • Analysis of molecular structures, mechanisms, and reported therapeutic outcomes.

Main Results:

  • Key categories include boron neutron capture therapy (BNCT) agents, enzyme inhibitors, benzoxaboroles, and ROS-targeting agents.
  • Boron agents exhibit diverse mechanisms, including targeted cell death induction and modulation of cellular processes.
  • Identified challenges include limited tumor selectivity, insufficient boron accumulation, and poor bioavailability.

Conclusions:

  • Boron-based small molecules represent a promising frontier in anticancer drug development.
  • Overcoming current challenges is crucial for realizing the full therapeutic potential of these agents.
  • Future research should focus on enhancing selectivity, accumulation, and bioavailability for improved clinical outcomes.